Healthy Skepticism International News
October 2002
REFERENCES
Armstrong, D., Reyburn, H. & Jones, R. (1996). A study of general practitioners’ reasons for changing their prescribing behaviour. British Medical Journal, 312, 949-952.
Association of Teachers of Ethics and Law in Australia and New Zealand Medical Schools (ATEAM). (2001). Position Statement: An ethics core curriculum for Australasian medical schools. Medical Journal of Australia, 175, 205-210.
Australian Medical Association. (1996). Code of Ethics. Position Statements [On-line]. Available: http://domino.ama.com.au/AMA/.
Avorn, J., Chren, M. & Hartley, R. (1982). Scientific vs commercial sources of influence on the prescribing behaviour of physicians. American Journal of Medicine, 73, 4-8.
Backer, E., Lebsack, J., Van Tonder, R. & Crabtree, B. (2000). The value of pharmaceutical representative visits and medication samples in community-based medicine. Journal of Family Practice, 49(9), 811-820.
Beary, J. (1996). Pharmaceutical marketing has real and proven value. Journal of General Internal Medicine, 11, 575-583.
Berings, D., Blondeel, L. & Habraken, H. (1994). The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. European Journal of Clinical Pharmacology, 46, 501-505.
Billig, M. (1987). Arguing and Thinking: A rhetorical approach to social psychology. Cambridge: Cambridge University Press.
Billig, M. (1991). Ideologies and beliefs. London: Sage.
Billig, M., Condor, S., Edwards, D., Gane, M., Middleton, D. & Radley, A. (1988). Ideological Dilemmas: A social psychology of everyday thinking. London: Sage Publications.
Bower, A. & Burkett, G. (1987). Family physicians and generic drugs. Journal of Family Practice, 24, 612-616.
Breen, K. (2001). Professional development and ethics for today’s and tomorrow’s doctors: There is no lack of ethical and professional challenges for doctors. Medical Journal of Australia, 175, 183-184.
Brotzman, G. & Mark, D. (1993). The effect on residents attitudes of regulatory policies regarding pharmaceutical representatives activities. Journal of General Internal Medicine, 8, 130-134.
Caudill, T., Johnson, M., Rich, E. & McKinney, P. (1996). Physicians, pharmaceutical sales representatives and the cost of prescribing. Archives of Family Medicine, 5, 201-206.
Chren, M. & Landefeld, C. (1994). Physicians’ behaviour and their interactions with drug companies. Journal of The American Medical Association, 271, 684-689.
Chren, M., Landefeld, C. & Murray, T. (1989). Doctors, drug companies, and gifts. Journal of The American Medical Association, 262, 3448-3451.
Gill, P., Freemantle, N., Bero, L., Haaijer-Ruskamp, F., Markela, M. & Barjesteh, K. (1996). GPs’ prescribing behaviour may be affected by drug promotion [Letter to the editor]. British Medical Journal, 313, 367.
Goddard, M., Henry, D. & Birkett, D. (2001). Costs and benefits: Securing the future of the pharmaceutical benefits scheme. Unpublished manuscript.
Goffman, I. (1981). Forms of Talk. Oxford: Basil Blackwell.
Greenhalgh, T. (1997). Papers that report drug trials (How to read a paper, part 6). British Medical Journal, 315, 480-484.
Griffith, D. (1999). Reasons for not seeing drug representatives. British Medical Journal, 319, 69-70.
Haayer, F. (1982). Rational prescribing and sources of information. Social Science of Medicine, 16, 2017-2023.
Jones, M., Greenfield, S. & Bradley, C. (2001). Prescribing new drugs: Qualitative study of influences on consultants and general practitioners. British Medical Journal, 323, 1-7.
Lexchin, J. (1989). Doctors and detailers: Therapeutic education or pharmaceutical promotion? International Journal of Health Sciences, 19, 663-679.
Lexchin, J. (1993). Interactions between physicians and the pharmaceutical industry: What does the literature say? Canadian Medical Association Journal, 149, 1401-1407.
Light, E. (2001, September 3). Docs charge reps for time [World round-up]. Australian Medicine, p. 2.
McKinney, W., Schiedermayer, D., Lurie, N., Simpson, D., Goodman, J. & Rich, E. (1990). Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. Journal of The American Medical Association, 264, 1693-1697.
Mansfield, P. (2001, Summer). Pushing expensive new drugs. Consuming Interest, p. 27-29.
Mansfield, P. & Lexchin, J. (2000). Scepticism and beliefs about new drugs. Unpublished manuscript.
Morelli, D. & Koenigsberg, M. (1992). Sample medication dispensing in a residency practice. Journal of Family Practice, 34, 42-47.
Moscovici, S. (1984). The phenomenon of social representations, in R. M. Farr and S. Moscovici (Eds.), Social Representations. Cambridge: Cambridge University Press.
Murphy, K. (1999, May 28). Guidelines on when to reject gift offers. Australian Doctor, p. 8.
Orlowski, J. & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns: There’s no such thing as a free lunch. Chest, 102(1), 270-273.
Peay, M. & Peay, R. (1988). The role of commercial sources in the adoption of a new drug. Social Science and Medicine, 26, 1183-1189.
Pomerantz, A. (1986). Extreme case formulations: A new way of legitimating claims. Human Studies, 9, 219-230.
Potter, J. (1996). Representing Reality: Discourse, rhetoric and social construction. London: SAGE Publications Ltd.
Potter, J. & Wetherell, M. (1987). Discourse and social psychology: Beyond attitudes and behaviour. London: SAGE Publications Ltd.
Roughead, E. (1995). The pharmaceutical representative and medical practitioner encounter: Implications for quality use of medicines. Unpublished master’s thesis, Latrobe University, Melbourne, Victoria, Australia.
Shaughnessy, A. & Slawson, D. (1996). Pharmaceutical representatives. British Medical Journal, 312, 1494-1995.
Siegal, D. & Lopez, J. (1997). Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing? Journal of The American Medical Association, 278, 1745-1748.
Steinman, M., Shlipak, M. & McPhee, S. (2001). Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. The American Journal of Medicine, 110, 551-557.
Susman, E. (2001, July 17). U.S. doctors touchy on topic of pharmaceutical gifts. The Medical Post, p. 9.
Thomson, A., Craig, B. & Barham, P. (1994). Attitudes of general practitioners in New Zealand to pharmaceutical representatives. British Journal of General Practice, 44, 220-226.
Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? The Journal of the American Medical Association, 283(3), 373-383.
Westfall, J., McCabe, J. & Nicholas, R. (1997). Personal use of drug samples be physicians and office staff. The Journal of the American Medical Association, 278, 141-143.
Westfall, J. (1998, June). Drug samples: Benefit or bait? [Letter in reply to letter to the editor]. The Journal of the American Medical Association, 279, 1698-1700.
Westfall, J. (2000). Physicians, pharmaceutical representatives, and patients: Who really benefits? Journal of Family Practice, 49(9), 817-820.
Wetherell, M. & Potter, J. (1992). Mapping the language of racism: Discourse and the legitimisation of exploitation. London: Harvester Wheatsheaf.
Wolf, B. (1998, June). Drug samples: Benefit or bait? [Letter to the editor]. The Journal of the American Medical Association, 279(21), 1698-1700.
Woolgar, S. & Pawluch, D. (1985). Ontological gerry-mandering: The anatomy of social problems explanations. Social Problems, 32, 214-227.
Ziegler, M., Lew, P. & Singer, B. (1995). The accuracy of drug information from pharmaceutical sales representatives. The Journal of the American Medical Association, 273, 1296-1298.
Comments
Our members can see and make comments on this page.
